Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patent Applications from Cold Spring Harbor Laboratory

NEW YORK, Jan. 22 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNAi-related patent applications from Cold Spring Harbor Laboratory, the company said today.

 

Alnylam, based in Cambridge, Mass., obtained a non-exclusive license for the therapeutic use of patent applications and related technology that cover gene silencing in mammalian cells by small interfering RNA.

 

CSHL's intellectual property in this area came out of research conducted by Gregory Hannon.

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.